BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

The IRF2BP2-KLF2 axis regulates osteoclast and osteoblast differentiation

  • Kim, Inyoung (Department of Pharmacology, Chonnam National University Medical School) ;
  • Kim, Jung Ha (Department of Pharmacology, Chonnam National University Medical School) ;
  • Kim, Kabsun (Department of Pharmacology, Chonnam National University Medical School) ;
  • Seong, Semun (Department of Pharmacology, Chonnam National University Medical School) ;
  • Kim, Nacksung (Department of Pharmacology, Chonnam National University Medical School)
  • Received : 2019.04.08
  • Accepted : 2019.05.25
  • Published : 2019.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Kruppel-like factor 2 (KLF2) has been implicated in the regulation of cell proliferation, differentiation, and survival in a variety of cells. Recently, it has been reported that KLF2 regulates the p65-mediated transactivation of $NF-{\kappa}B$. Although the $NF-{\kappa}B$ pathway plays an important role in the differentiation of osteoclasts and osteoblasts, the role of KLF2 in these bone cells has not yet been fully elucidated. In this study, we demonstrated that KLF2 regulates osteoclast and osteoblast differentiation. The overexpression of KLF2 in osteoclast precursor cells inhibited osteoclast differentiation by downregulating c-Fos, NFATc1, and TRAP expression, while KLF2 overexpression in osteoblasts enhanced osteoblast differentiation and function by upregulating Runx2, ALP, and BSP expression. Conversely, the downregulation of KLF2 with KLF2-specific siRNA increased osteoclast differentiation and inhibited osteoblast differentiation. Moreover, the overexpression of interferon regulatory protein 2-binding protein 2 (IRF2BP2), a regulator of KLF2, suppressed osteoclast differentiation and enhanced osteoblast differentiation and function. These effects were reversed by downregulating KLF2. Collectively, our data provide new insights and evidence to suggest that the IRF2BP2/KLF2 axis mediates osteoclast and osteoblast differentiation, thereby affecting bone homeostasis.

Keywords

References

  1. Leibbrandt A and Penninger JM (2008) RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci 1143, 123-150 https://doi.org/10.1196/annals.1443.016
  2. Kim JH and Kim N (2016) Signaling Pathways in Osteoclast Differentiation. Chonnam Med J 52, 12-17 https://doi.org/10.4068/cmj.2016.52.1.12
  3. Takayanagi H, Kim S, Koga T et al (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3, 889-901 https://doi.org/10.1016/S1534-5807(02)00369-6
  4. Katagiri T and Takahashi N (2002) Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis 8, 147-159 https://doi.org/10.1034/j.1601-0825.2002.01829.x
  5. Matsubara T, Kida K, Yamaguchi A et al (2008) BMP2 regulates Osterix through Msx2 and Runx2 during osteoblast differentiation. J Biol Chem 283, 29119-29125 https://doi.org/10.1074/jbc.M801774200
  6. Schroeder TM, Jensen ED and Westendorf JJ (2005) Runx2: a master organizer of gene transcription in developing and maturing osteoblasts. Birth Defects Res C Embryo Today 75, 213-225 https://doi.org/10.1002/bdrc.20043
  7. Boyce BF, Yao Z and Xing L (2010) Functions of nuclear factor kappaB in bone. Ann N Y Acad Sci 1192, 367-375 https://doi.org/10.1111/j.1749-6632.2009.05315.x
  8. Kim I, Kim JH, Kim K, Seong S and Kim N (2017) Tusc2/Fus1 regulates osteoclast differentiation through NF-kappaB and NFATc1. BMB Rep 50, 454-459 https://doi.org/10.5483/BMBRep.2017.50.9.026
  9. Bak SU, Kim S, Hwang HJ et al (2017) Heme oxygenase-1 (HO-1)/carbon monoxide (CO) axis suppresses RANKL-induced osteoclastic differentiation by inhibiting redox-sensitive NF-kappaB activation. BMB Rep 50, 103-108 https://doi.org/10.5483/BMBRep.2017.50.2.220
  10. Yamashita T, Yao Z, Li F et al (2007) NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem 282, 18245-18253 https://doi.org/10.1074/jbc.M610701200
  11. Yamazaki M, Fukushima H, Shin M et al (2009) Tumor necrosis factor alpha represses bone morphogenetic protein (BMP) signaling by interfering with the DNA binding of Smads through the activation of NF-kappaB. J Biol Chem 284, 35987-35995 https://doi.org/10.1074/jbc.M109.070540
  12. Yao Z, Li Y, Yin X, Dong Y, Xing L and Boyce BF (2014) NF-kappaB RelB negatively regulates osteoblast differentiation and bone formation. J Bone Miner Res 29, 866-877 https://doi.org/10.1002/jbmr.2108
  13. Lee J, Youn BU, Kim K et al (2015) Mst2 Controls Bone Homeostasis by Regulating Osteoclast and Osteoblast Differentiation. J Bone Miner Res 30, 1597-1607 https://doi.org/10.1002/jbmr.2503
  14. Nayak L, Goduni L, Takami Y et al (2013) Kruppel-like factor 2 is a transcriptional regulator of chronic and acute inflammation. Am J Pathol 182, 1696-1704 https://doi.org/10.1016/j.ajpath.2013.01.029
  15. Dang DT, Pevsner J and Yang VW (2000) The biology of the mammalian Kruppel-like family of transcription factors. Int J Biochem Cell Biol 32, 1103-1121 https://doi.org/10.1016/S1357-2725(00)00059-5
  16. Das H, Kumar A, Lin Z et al (2006) Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes. Proc Natl Acad Sci U S A 103, 6653-6658 https://doi.org/10.1073/pnas.0508235103
  17. Das M, Lu J, Joseph M et al (2012) Kruppel-like factor 2 (KLF2) regulates monocyte differentiation and functions in mBSA and IL-1beta-induced arthritis. Curr Mol Med 12, 113-125 https://doi.org/10.2174/156652412798889090
  18. Childs KS and Goodbourn S (2003) Identification of novel co-repressor molecules for Interferon Regulatory Factor-2. Nucleic Acids Res 31, 3016-3026 https://doi.org/10.1093/nar/gkg431
  19. Carneiro FR, Ramalho-Oliveira R, Mognol GP and Viola JP (2011) Interferon regulatory factor 2 binding protein 2 is a new NFAT1 partner and represses its transcriptional activity. Mol Cell Biol 31, 2889-2901 https://doi.org/10.1128/MCB.00974-10
  20. Teng AC, Kuraitis D, Deeke SA et al (2010) IRF2BP2 is a skeletal and cardiac muscle-enriched ischemia-inducible activator of VEGFA expression. FASEB J 24, 4825-4834 https://doi.org/10.1096/fj.10-167049
  21. Chen HH, Keyhanian K, Zhou X et al (2015) IRF2BP2 Reduces Macrophage Inflammation and Susceptibility to Atherosclerosis. Circ Res 117, 671-683 https://doi.org/10.1161/CIRCRESAHA.114.305777
  22. Jha P and Das H (2017) KLF2 in Regulation of NF-kappaB-Mediated Immune Cell Function and Inflammation. Int J Mol Sci 18, 2383-2420 https://doi.org/10.3390/ijms18112383
  23. SenBanerjee S, Lin Z, Atkins GB et al (2004) KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med 199, 1305-1315 https://doi.org/10.1084/jem.20031132
  24. Boyce BF, Xiu Y, Li J, Xing L and Yao Z (2015) NF-kappaB-Mediated Regulation of Osteoclastogenesis. Endocrinol Metab (Seoul) 30, 35-44 https://doi.org/10.3803/EnM.2015.30.1.35
  25. Chang J, Wang Z, Tang E et al (2009) Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat Med 15, 682-689 https://doi.org/10.1038/nm.1954
  26. Cao Z, Sun X, Icli B, Wara AK and Feinberg MW (2010) Role of Kruppel-like factors in leukocyte development, function, and disease. Blood 116, 4404-4414 https://doi.org/10.1182/blood-2010-05-285353
  27. Zhang H and Reilly MP (2015) IRF2BP2: A New Player at the Crossroads of Inflammation and Lipid Metabolism. Circ Res 117, 656-658 https://doi.org/10.1161/CIRCRESAHA.115.307245
  28. Zhou B, Cron RQ, Wu B et al (2002) Regulation of the murine Nfatc1 gene by NFATc2. J Biol Chem 277, 10704-10711 https://doi.org/10.1074/jbc.M107068200
  29. Ikeda F, Nishimura R, Matsubara T et al (2004) Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 114, 475-484 https://doi.org/10.1172/JCI200419657